BPG is committed to discovery and dissemination of knowledge
Case Report
©The Author(s) 2022.
World J Clin Cases. Sep 16, 2022; 10(26): 9470-9477
Published online Sep 16, 2022. doi: 10.12998/wjcc.v10.i26.9470
Figure 1
Figure 1 Imaging findings. A: On January 29, 2021, computed tomography (CT) showed multiple space-occupying lesions in the ileocecal bowel, peritoneum and omentum, and the boundary with the right psoas major muscle was unclear (red arrow); B: After 3 courses of chemotherapy, CT showed that the multiple space- occupying lesions in the ileocecal bowel, peritoneum and omentum had significantly shrunk, and the boundary with the right psoas major muscle was obvious (red arrow); C: On February 3, 2021, B-ultrasound showed a solid hypoechoic mass 1.89 cm × 1.61 cm in size with a clear boundary in the lower segment of the right anterior lobe (red arrow); D: On March 12, 2021, positron emission tomography (PET)-CT showed a soft tissue mass shadow in the liver and right lower abdomen, surrounding the ileocecal junction, with a maximum standardized uptake value of 30.3. Radioactive uptake in the hepatic capsule margin, abdominal and pelvic mesangium and omentum was significantly increased; E: On September 24, 2021, after 6 courses of chemotherapy, PET-CT showed that there was no obvious mass or increased fluorodeoxyglucose metabolism in the abdominal and pelvic peritoneal mesangium, and no obvious increased radioactive uptake in the liver (white arrow).


Write to the Help Desk